Literature DB >> 28101628

Rho kinase inhibitor fasudil mitigates high-cholesterol diet-induced hypercholesterolemia and vascular damage.

Nibrass Taher Abdali1, Awny H Yaseen2, Eman Said3, Tarek M Ibrahim1.   

Abstract

The current study was designed to investigate the potential beneficial therapeutic outcome of Rho kinase inhibitor (fasudil) against hypercholesterolemia-induced myocardial and vascular injury in rabbits together with diet modification. Sixteen male rabbits were randomly divided into four groups: normal control group which received standard rabbit chow, hypercholesterolemic control group, and treated groups which received cholesterol-rich rabbit chow (1.5% cholesterol) for 8 weeks. Treated groups received either fasudil (100 mg/kg/day) or rosuvastatin (2.5 mg/kg/day) starting from the ninth week for further 4 weeks with interruption of the cholesterol-rich chow. Biochemical assessment of serum cholesterol, triglyceride, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and myocardial oxidative/antioxidant biomarkers malondialdehyde (MDA), superoxide dismutase (SOD), and reduced glutathione (GSH), besides biochemical assessment of serum nitric oxide (NO), creatine kinase (CK), and lactate dehydrogenase (LDH) activities and serum total antioxidant capacity (TAC), was conducted. Serum vascular cell adhesion molecule 1 (VCAM-1) and serum Rho-associated protein kinase 1 (ROCK-1) were also evaluated along with histopathological examination of aorta specimens. Fasudil administration significantly decreased serum cholesterol, triglyceride (TG), and LDL and significantly increased serum HDL, with concomitant decrease in serum CK and LDH activities, NO, and restoration of serum TAC. Myocardial MDA significantly declined; SOD activity and GSH contents were restored. Serum ROCK-1 and VCAM-1 levels significantly declined as well. Vascular improvement was confirmed with histopathological examination, which revealed normal aortic intema with the absence of atheromas. Fasudil has promising anti-atherogenic activity mediated primarily via alleviation of hypercholesterolemia-induced oxidative stress and modulation of inflammatory response.

Entities:  

Keywords:  Atherosclerosis; Fasudil; Hypercholesterolemia; Rho kinase inhibitor; Rosuvastatin; VCAM

Mesh:

Substances:

Year:  2017        PMID: 28101628     DOI: 10.1007/s00210-017-1343-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  52 in total

1.  Heart healthy diets for all children: no longer controversial.

Authors:  M S Jacobson
Journal:  J Pediatr       Date:  1998-07       Impact factor: 4.406

2.  Rho kinase inhibition by fasudil exerts antioxidant effects in hypercholesterolemic rats.

Authors:  Zhihong Ma; Jianping Zhang; Ensheng Ji; Gang Cao; Guoming Li; Li Chu
Journal:  Clin Exp Pharmacol Physiol       Date:  2011-10       Impact factor: 2.557

3.  Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease.

Authors:  Ruba S Deeb; Brian D Lamon; David P Hajjar
Journal:  Curr Hypertens Rev       Date:  2009-11-01

Review 4.  Therapeutic potential of rho-kinase inhibitors in cardiovascular diseases.

Authors:  Yoshitaka Hirooka; Hiroaki Shimokawa
Journal:  Am J Cardiovasc Drugs       Date:  2005       Impact factor: 3.571

5.  A Rho-kinase inhibitor, fasudil, prevents development of diabetes and nephropathy in insulin-resistant diabetic rats.

Authors:  Yuichi Kikuchi; Muneharu Yamada; Toshihiko Imakiire; Taketoshi Kushiyama; Keishi Higashi; Naomi Hyodo; Kojiro Yamamoto; Takashi Oda; Shigenobu Suzuki; Soichiro Miura
Journal:  J Endocrinol       Date:  2007-03       Impact factor: 4.286

6.  Rho kinase inhibitor Fasudil induces neuroprotection and neurogenesis partially through astrocyte-derived G-CSF.

Authors:  Jing Ding; Jie-Zhong Yu; Qin-Ying Li; Xin Wang; Chuan-Zhen Lu; Bao-Guo Xiao
Journal:  Brain Behav Immun       Date:  2009-05-15       Impact factor: 7.217

Review 7.  Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.

Authors:  Huseyin Naci; Jasper J Brugts; Rachael Fleurence; Bernice Tsoi; Harleen Toor; A E Ades
Journal:  Eur J Prev Cardiol       Date:  2013-02-27       Impact factor: 7.804

Review 8.  The LDL modification hypothesis of atherogenesis: an update.

Authors:  Daniel Steinberg
Journal:  J Lipid Res       Date:  2008-11-15       Impact factor: 5.922

9.  Fasudil inhibits ER stress-induced VCAM-1 expression by modulating unfolded protein response in endothelial cells.

Authors:  Daiji Kawanami; Keiichiro Matoba; Rina Okada; Masami Tsukamoto; Jun Kinoshita; Sho Ishizawa; Yasushi Kanazawa; Tamotsu Yokota; Kazunori Utsunomiya
Journal:  Biochem Biophys Res Commun       Date:  2013-05-07       Impact factor: 3.575

Review 10.  The vascular endothelium and human diseases.

Authors:  Peramaiyan Rajendran; Thamaraiselvan Rengarajan; Jayakumar Thangavel; Yutaka Nishigaki; Dhanapal Sakthisekaran; Gautam Sethi; Ikuo Nishigaki
Journal:  Int J Biol Sci       Date:  2013-11-09       Impact factor: 6.580

View more
  2 in total

1.  RhoA/ROCK2 signalling is enhanced by PDGF-AA in fibro-adipogenic progenitor cells: implications for Duchenne muscular dystrophy.

Authors:  Esther Fernández-Simón; Xavier Suárez-Calvet; Ana Carrasco-Rozas; Patricia Piñol-Jurado; Susana López-Fernández; Gemma Pons; Joan Josep Bech Serra; Carolina de la Torre; Noemí de Luna; Eduard Gallardo; Jordi Díaz-Manera
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-07       Impact factor: 12.910

2.  The Effects of RKI-1447 in a Mouse Model of Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet and in HepG2 Human Hepatocellular Carcinoma Cells Treated with Oleic Acid.

Authors:  Jinshan Wang; Wentao Jiang
Journal:  Med Sci Monit       Date:  2020-02-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.